CRVO Stock Risk & Deep Value Analysis

CervoMed Inc

DVR Score

6.5

out of 10

Solid Pick

The Bottom Line on CRVO

We analyzed CervoMed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran CRVO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Jun 16, 2026•Run Fresh Analysis →•

Get notified when CRVO moves

Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.

📈CRVO Performance Overview3yr weekly

📊

Unlock CRVO Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

CRVO Quality Rating

8.0

Growth

2.0

Profitability

4.0

Health

5.0

Capital allocation

7.0

Momentum

CRVO Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

CRVO Deep Value Analysis

CervoMed (CRVO) is a high-risk, high-reward clinical-stage biotech with significant 10x potential if its lead candidate, neflamapimod, succeeds in Phase 3 trials for dementia with Lewy bodies (DLB). The market opportunity in age-related brain disorders is massive and underserved. Recent insider buying and a successful private placement extending the cash runway to Q2 2027 are positive signals, despite ongoing cash burn and widening losses. The company faces substantial financial and execution risk inherent to drug development, but the potential for market leadership in DLB provides significant upside. Analyst sentiment is moderately bullish, but profitability remains a distant goal.

CRVO Research Sources

Research sources(3 linked articles)

For educational context only. Not financial advice.

CRVO Red Flags & Warning Signs

⚠
Q2 2026 Earnings Report (estimated August 14, 2026): A significant increase in cash burn without corresponding clinical progress updates could reduce runway projections, necessitating earlier and potentially more dilutive financing.
⚠
Failure to achieve sufficient patient enrollment in neflamapimod Phase 3 DLB trials (Q3 2026 onwards): Delays or inability to recruit patients could push back clinical timelines, increasing costs and extending the period until potential commercialization.

Unlock CRVO Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

CRVO Financial Health Metrics

Market Cap

$22.96M

Profit Margin

-1056.59%

Beta (Volatility)

-0.59

Earnings Per Share

$-3.27

CRVO Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

1 Identified

Intangible Assets/IP

The moat's durability hinges entirely on the successful development and regulatory approval of neflamapimod, which would grant patent protection and market exclusivity. If the drug fails clinical trials or faces strong competition from superior therapies, the nascent moat would dissolve.

CRVO Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

CRVO Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q2 2026 Earnings Report (estimated August 14, 2026): Key focus on cash burn rate, operating expenses, and any updates on neflamapimod clinical program progress, particularly Phase 3 DLB enrollment.
•Initiation of neflamapimod Phase 3 DLB program enrollment (anticipated Q3/Q4 2026): Successful patient enrollment signaling advancement towards critical efficacy data, validating the $10.5M private placement proceeds.

Medium-Term (6-18 months)

•Strategic partnership or licensing deal for neflamapimod (6-18 months): Collaboration with a larger pharmaceutical company for co-development or commercialization, potentially bringing in non-dilutive capital and commercial expertise, substantially reducing financial risk.
•Interim Phase 3 clinical data release for neflamapimod (late 2027/early 2028): Any positive safety or early efficacy signals could trigger a major re-rating as the market discounts future approval odds, potentially adding hundreds of millions to market cap.

Long-Term (18+ months)

•Successful completion of neflamapimod Phase 3 clinical trials in DLB (2029-2030): If positive, this would pave the way for NDA filing and potential FDA approval, positioning CervoMed as a leader in a multi-billion dollar market segment.
•Expansion of neflamapimod pipeline into additional indications like stroke recovery or ALS (2030+): Successful data in these areas could unlock additional revenue streams, allowing the company to reach a $1.0B+ market cap based on multiple therapeutic franchises.

Catalysts & Growth Drivers

CRVO Bull Case: What Could Go Right

✓
Watch for initiation and progress reports on neflamapimod's Phase 3 DLB enrollment — successful patient recruitment signals timely advancement.
✓
Monitor the company's cash balance and cash burn rate in quarterly reports — a sustained reduction in cash runway below 6-9 months would indicate heightened financial risk.

Bull Case Analysis

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for CervoMed Inc (CRVO)?

As of June 16, 2026, CervoMed Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of CervoMed Inc?

CervoMed Inc's market capitalization is approximately $23.0M..

What is the risk level for CRVO stock?

Our analysis rates CervoMed Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

Is CervoMed Inc's revenue growing?

CervoMed Inc has reported revenue growth of -78.5%. Revenue has been declining, which warrants closer examination.

Is CRVO stock profitable?

CervoMed Inc has a profit margin of -1056.6%. The company is currently unprofitable.

How often is the CRVO DVR analysis updated?

Our AI-powered analysis of CervoMed Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 16, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.